Drug company Roche India said on Wednesday that it had received Emergency Use Authorization (EUA) from the Central Drugs Standards Control Organization (CDSCO) for Roche’s investigational antibody cocktail used in the treatment of Covid-19. Roche India said in a statement that the approval of the antibody cocktail of Casirivimab and Imdevimab in India is based on data filed for the EUA in the US and the scientific opinion of the Committee for Medical Products for Human Use (CHMP) in the European Union.
The statement said that the antibody cocktail would be given for the treatment of low and moderate corona virus disease. It is intended for adults and pediatric patients (people 12 years of age or older who weigh at least 40 kg), who have been confirmed to have infection with SARS-COV2 and to develop severe COVID-19 disease. The big ones are at greater risk. It further states that this can help patients of sufficiently high risk before their condition worsens.
